Integrated directly with our multi-ton solid-phase peptide synthesis (SPPS) manufacturing infrastructure. Batch-verified purity, stable supply chains, and global compliance dossiers.
Cellular senescence represents an irreversible cell cycle arrest driven by telomere erosion, oxidative stress, oncogene activation, and DNA damage. Unlike normal senescent clearance, accumulation of senescent cells drives tissue degradation via the Senescence-Associated Secretory Phenotype (SASP).
Standard L-peptides exhibit in vivo half-lives measured in minutes due to ubiquitous serum and tissue endopeptidases. FOXO4-DRI is engineered with an inverted primary sequence constructed exclusively from D-amino acids. This preserves native spatial side-chain topology while rendering the backbone impervious to enzymatic degradation, extending pharmacological residency across preclinical models.
Senescent cells evade programmed death through the hyper-stabilized sequestration of transcription factor p53 by endogenous FOXO4. FOXO4-DRI selectively competitive-inhibits this specific interface. By dislodging p53 from FOXO4, p53 translocates from the nucleus to the mitochondria, activating downstream Caspase-3/9 cleavage cascades to trigger selective apoptosis in senescent cells while leaving healthy somatic cells viable.
Synthesized with an integrated, cationic cell-penetrating peptide (CPP) derived from the HIV-TAT transduction domain, our FOXO4-DRI construct achieves direct macropinocytosis across mammalian lipid bilayers. Thinheal’s specialized synthesis protects this dense basic domain from premature aggregation during assembly and deprotection.
As longevity biotechnology shifts from exploratory biology to clinical evaluation, high-purity Fox04 peptide APIs serve distinct translational sectors worldwide.
Senescent myofibroblasts drive progressive collagen deposition in idiopathic pulmonary fibrosis (IPF) and cirrhosis. Selective FOXO4 disruption attenuates the profibrotic cytokine cascade (TGF-β, IL-6), restoring parenchymal plasticity.
Endothelial senescence impairs nitric oxide synthase expression, accelerating plaque calcification. In vivo delivery models demonstrate that targeted senolytic therapy clears damaged intimal endothelium, enhancing arterial lumen compliance.
Senescent chondrocytes drive extracellular matrix breakdown by secreting MMP-13 and ADAMTS5. Localized intra-articular administration of FOXO4-DRI eradicates catabolic cells, creating a microenvironment permissive to autologous chondrocyte proliferation.
Radiation and chemotherapeutic regimens (e.g., doxorubicin, cisplatin) induce Therapy-Induced Senescence (TIS). While tumors regress initially, residual senescent cells drive metastatic recurrence. FOXO4-DRI functions as a post-therapy clearance agent.
The chemical synthesis of long, highly basic peptides such as FOXO4-DRI (44 amino acids containing dense arginine/lysine clusters) presents significant bottlenecks: sterically hindered coupling steps, high reagent costs, and challenging purification profiles.
At Hangzhou Thinheal Pharma-Tech Co., Ltd., we resolve these industry bottlenecks through our integrated synthesis base in Zhejiang, China:
Understanding the analytical thresholds separating catalog biochemical reagents from clinical-ready Fox04 peptide APIs. Every Thinheal batch undergoes orthogonal verification.
| Analytical Parameter | Common Catalog Grade | Thinheal API / CDMO Grade | Testing Methodology |
|---|---|---|---|
| Chemical Purity | ≥ 90.0% – 95.0% | ≥ 98.5% (Single max impurity < 0.5%) | Analytical RP-HPLC (C18 / C4, 214nm & 280nm) |
| Identity & Mass Accuracy | Nominal mass match | Exact Theoretical Match (±0.5 Da) | High-Resolution ESI-MS / MALDI-TOF |
| Chiral Optical Purity | Unspecified / Incomplete test | ≥ 99.5% D-Amino Acid Retention | Chiral Gas Chromatography – Mass Spec (GC-MS) |
| Counter-Ion Profiling | Trifluoroacetic Acid (TFA) residual | Custom Acetate / Formate Exchange (<1% TFA) | Ion Chromatography (IC) with Suppressed Conductivity |
| Bacterial Endotoxin | Not monitored (>10 EU/mg common) | ≤ 0.05 EU/mg (Aseptic Injection Grade) | Kinetic Turbidimetric Limulus Amebocyte Lysate (LAL) |
| Residual Solvents (DMF, ACN) | Uncontrolled | ICH Q3C Compliant (DMF < 880 ppm) | Headspace Gas Chromatography (HS-GC-FID) |
| Water & Peptide Content | Gross weight (often 60-70% peptide) | Net Peptide Content ≥ 82.0% | Karl Fischer Coulometry + Elemental Nitrogen / AAA |
Our Quality Assurance management system maintains comprehensive traceability from amino acid raw materials through cleavage, preparative chromatography, lyophilization, and final vialing. Full batch manufacturing records (BMR) support global IND/NDA submissions.
Seamless cross-border procurement facilitated by four multilingual trade desks: North America & Western Europe, Russia & CIS, Southeast Asia, and the Middle East. Real-time regulatory assistance, custom harmonized tariff classification, and localized logistics.
Lyophilized peptides are susceptible to hygroscopic clumping and peptide bond degradation if exposed to elevated temperatures. We dispatch all international consignments via temperature-monitored vacuum insulation panels with real-time temperature loggers.
Everything procurement executives, formulation scientists, and life science investigators need to know before initiating custom Fox04 synthesis campaigns.
FOXO4-DRI is a synthetic 44-amino-acid peptide engineered as a D-retro-inverso analogue of the interaction domain between FOXO4 and p53. Its primary retro-inverso sequence consists of all D-amino acids: H-D-Arg-D-Lys-D-Lys-D-Arg-D-Arg-D-Gln-D-Arg-D-Arg-D-Arg-D-Pro-D-Pro-D-Pro-D-Arg-D-Lys-D-Gly-D-Gly-D-Ser-D-Arg-D-Arg-D-Asn-D-Ala-D-Trp-D-Gly-D-Asn-D-Gln-D-Ser-D-Tyr-D-Ala-D-Glu-D-Leu-D-Ile-D-Ser-D-Gln-D-Ala-D-Ile-D-Glu-D-Ser-D-Ala-D-Pro-D-Glu-D-Lys-D-Arg-D-Leu-D-Thr-NH2. The theoretical chemical formula is approximately C211H369N77O63, with an average monoisotopic molecular weight of 5358.1 g/mol.
Enantiomeric integrity is paramount for retro-inverso efficacy. We utilize chiral Gas Chromatography-Mass Spectrometry (GC-MS) following complete peptide acid deuterated hydrolysis to verify the optical purity of individual amino acid constituents. Every incoming lot of Fmoc-D-amino acid building blocks is subjected to strict polarimetric and chiral HPLC testing to confirm ≥99.5% D-enantiomeric purity prior to solid-phase assembly.
Standard solid-phase cleavage utilizes Trifluoroacetic Acid (TFA), leaving basic peptides with substantial residual TFA salt (frequently 15–25% by weight). TFA exhibits intrinsic cytotoxicity in cellular assays and in vivo models, confounding longevity study endpoints. Thinheal employs an ion-exchange chromatography step using ammonium acetate / dilute acetic acid mobile phases to guarantee acetate counter-ion conversion with residual TFA reduced below 1.0% or 0.1% upon client specification.
Due to its strong amphipathic structure and basic TAT sequence, FOXO4-DRI demonstrates high solubility in sterile deionized water or bacteriostatic water up to 10 mg/mL. For physiological buffer preparations (PBS, saline), initial dissolution in a minimal volume of sterile water or 10% dilute acetic acid/DMSO before diluting into isotonic saline prevents electrostatic precipitation. Reconstituted solutions should be aliquoted and stored at -80°C to prevent freeze-thaw degradation.
Every shipment arrives with a comprehensive Certificate of Analysis (CoA) encompassing: RP-HPLC chromatograms (demonstrating purity and individual impurity percentages), High-Resolution Mass Spectrometry (HRMS) confirming molecular weight, Karl Fischer water determination, net peptide content analysis via quantitative Amino Acid Analysis (AAA), residual solvent gas chromatography, and endotoxin quantification via kinetic turbidimetric LAL testing.
Thinheal accommodates projects ranging from discovery-stage custom pilot synthesis (1g, 5g, 10g) up to multi-kilogram commercial production campaigns. Leveraging automated large-bore SPPS reactors and multi-ton factory output in Hangzhou, we can scale seamlessly from exploratory batches directly into registration stability lots without process re-validation.
Small molecule senolytic cocktails (such as D+Q or Fisetin) operate via broad-spectrum kinase and pathway inhibition, which often induces off-target toxicity in healthy hepatic, renal, or hematopoietic cells. FOXO4-DRI is a targeted peptide-protein interaction (PPI) disrupter that specifically exploits the hyper-reliance of senescent cells on the FOXO4-p53 complex, achieving selective apoptosis without systemic cytopenia.
In its lyophilized, desalted powder state stored at -20°C (or -80°C for long-term reserves), FOXO4-DRI demonstrates validated stability exceeding 24 months with no measurable loss in chromatographic purity or sequence truncation. Shipments packed with dry ice or validated gel refrigerant maintain integrity across standard international flight durations.
Yes. Our custom CDMO platform routinely synthesizes N-terminal or C-terminal conjugated FOXO4-DRI constructs, including FITC, Cy5, Biotin, Palmitoyl lipidations (for half-life extension), and isotope-labeled variants (13C, 15N) for pharmacokinetics (PK) tracing and cellular biodistribution studies.
For pharmaceutical and biotech sponsors advancing toward clinical trials, Thinheal provides regulatory submission packages including Drug Master File (DMF) documentation, analytical method validation reports (ICH Q2(R1)), forced degradation stability data, and complete raw material provenance filings.
Explore our broader industrial portfolio manufactured in accordance with strict pharmacopeial monographs and commercial purity criteria.
Whether securing pilot gram quantities for in vitro validation or reserving dedicated synthesis reactor capacity for multi-kilogram senolytic campaigns, Hangzhou Thinheal Pharma-Tech delivers verified chiral purity, rapid delivery, and global regulatory coordination.
Thin